Novalis Biotech
Novalis Biotech is an early-stage venture capital firm focused on life sciences, particularly in the realm of enabling technologies. The firm emphasizes capital-light platform technologies and close customer interaction from the early stages of a company's life. Novalis invests in innovative research and manufacturing tools, bioinformatics, genomics, diagnostics, and digital health, supporting early-stage startups from pre-seed to Series A. The firm aims to create value for stakeholders by providing funding, leveraging professional and academic connections, and shaping business strategies.
Novalis Biotech
What We Do
Novalis Biotech provides funding to early-stage startups, particularly in the life sciences sector, focusing on enabling technologies.
The firm offers strategic guidance to startups, helping them shape their business strategies to create value for stakeholders.
Novalis shares its professional and academic connections with portfolio companies to support their growth and development.
Novalis helps startups in shaping their business strategies to ensure value creation for all stakeholders.
Industry Focus
Portfolio
Specializes in rheumatology and rheumatological radiology using AI to detect early signs of joint damage.
#Medical Imaging AI
Develops ultrasensitive multiplex assays for detecting rare nucleic acid sequences.
#Molecular Biotech
Focuses on the diagnosis and management of cough-incident medical conditions.
#Digital Health
Developed BRB-seq technology for cost-effective RNA sequencing. Recently raised CHF 1 million in seed financing led by Novalis Biotech to enable commercialization and scale-up of its unique RNA sequencing technology.
#RNA Sequencing
Advances cell-based science and therapeutics with its LumiPore transfection platform.
#Cell-based Science
Developed a multimodal assessment platform for tracking neurological and psychiatric diseases.
#Neurological and Psychiatric Assessment
Revolutionizes detection of bio and chemical compounds with graphene-based technology.
#Biosensing Technology
Develops Enzypad, a near-patient diagnostic device for blood coagulation. Recently announced a strategic partnership with Takeda to accelerate development of its diagnostic technology platform for hemophilia patients.
#Diagnostic Technology
Provides kits and services based on Targeted Locus Amplification (TLA) technology.
#Genomics
Develops epigenetic biomarkers for cancer diagnosis and personalized treatment.
#Epigenetic Biomarkers
Pioneers immunotherapies to fight cancer using its ImmunoEngine discovery platform.
#Biopharmaceutical
Key People
Investment Manager
Co-founder / Managing Director
Co-founder / Managing Director
Fund Manager
Member of the Supervisory Board
Advisory board member